Trial · NCT01802489
Amiloride Clinical Trial In Optic Neuritis
NCT01802489, Phase 2, Completed, University of Oxford
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Amiloride Clinical Trial In Optic Neuritis. Trials, record NCT01802489. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01802489
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Amiloride Clinical Trial In Optic Neuritis
- NCT number
- NCT01802489
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 46 participants, actual
- Lead sponsor
- University of Oxford
- Conditions
- Optic Neuritis, Multiple Sclerosis
- Interventions
- Amiloride, Placebo
- First posted
- 2013-03-01
- Last updated
- 2018-05-17
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Scanning laser polarimetry determined retinal nerve fibre layer thickness | Baseline, 6 and 12 months | The primary outcome will be difference in retinal nerve fibre thickness at 6 months between affected eye and non-affected fellow eye at baseline between the amiloride and placebo group. An additional measure will be made at 12 months |
| Secondary | Optical coherence tomography determined difference in retinal nerve fibre layer thickness. | Baseline, 6 and 12 months | Difference in thickness at 6 months and 12 months between affected eye and non-affected fellow eye at baseline, between the amiloride and placebo group |
| Secondary | Differences between the amiloride and placebo groups in non-conventional MRI surrogate marker of white matter and grey matter injury and connectivity by 3T scanning. | Baseline, 6 and 12 months | * Diffusion weighted imaging (DWI) - measures; fractional anisotropy (FA), mean diffusivity (MD), axial and radial diffusivity (RD) of the posterior visual tracts * High Resolution T1-weighted image measure of grey matter volume * Magnetic resonance spectroscopy (MRS) measures of N-acetyl aspartate (NAA) in the visual cortex * Resting state functional MRI (RS fMRI) patterns of activity * Magnetisation transfer imaging (MTI) derived magnetisation transfer ratio (MTR) of the white and grey matter |
| Secondary | Visual Function | Baseline, 6 and 12 months | * High and low contrast (2.5% and 1.25%) visual acuity. * Farnsworth Munsell 100 Hue (FM100) colour vision test. |
| Secondary | Visual Electrophysiology | 0 and 6 months | Differences in visually evoked potential and pattern electro-retinogram between the amiloride and placebo groups as additional measures of visual function |
| Secondary | Quality of life questionnaires | Baseline, 6 and 12 months | * 25 point national institutes for health visual function questionnaire * 10 point neuro ophthalmic supplement. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01802489
GET https://conductscience.org/api/trials/v1/NCT01802489/registered